Novo Nordisk 's U.S. shares plummeted Tuesday after the company said it sees sales and profit growth declining this year, hit by lower prices in the U.S. and loss of exclusivity for its blockbuster Wegovy and Ozempic in China, Brazil and Canada. Novo's American depositary shares fell 14% as of 12:35 pm ET, after a trading halt. The results were published after the closing bell in Copenhagen, where the company has its primary listing, and ahead of the scheduled release early Wednesday. For 2026,